Gan & Lee Pharmaceuticals

Gan & Lee Pharmaceuticals is a leading global biopharmaceutical company specializing in the research, development, production, and commercialization of insulin analogs and innovative diabetes treatments. Founded in 1998, the company was the first in China to develop domestic biosynthetic human insulin and has since expanded its portfolio to include a full range of insulin products, including long-acting, rapid-acting, and premixed formulations. The company is currently pivoting toward innovative metabolic therapies, with a robust pipeline featuring bi-weekly GLP-1 receptor agonists and once-weekly basal insulins. Gan & Lee maintains a significant international presence, with products registered in over 20 countries and a strategic US headquarters in Bridgewater, New Jersey, to oversee global clinical development and regulatory affairs.